One in 10 people in America is fighting a rare disease, or a disorder that affects fewer than 200,000 Americans. Although there are more than 7,000 rare diseases that collectively affect more than 350 million people worldwide, it is not profitable for the pharmaceutical industry to develop new therapies to treat the small number of people suffering from each rare condition.
Researchers at the LSU Computational Systems Biology group have developed a sophisticated and systematic way to identify existing drugs that can be repositioned to treat a rare disease or condition. They have fine-tuned a computer-assisted drug repositioning process that can save time and money in helping these patients receive effective treatment.
“Rare diseases sometimes affect such a small population that discovering treatments would not be financially feasible unless through humanitarian and governmental incentives. These conditions that are sometimes left untreated are labeled ‘orphan diseases.’ We developed a way to computationally find matches between rare disease protein structures and functions and existing drug interactions that can help treat patients with some of these orphan diseases,” said Misagh Naderi, one of the paper’s lead authors and a doctoral candidate in the LSU Department of Biological Sciences.
This research will be published this week in the npj Systems Biology and Applications journal, published by the Nature Publishing Group in partnership the Systems Biology Institute.
“In the past, most repurposed drugs were discovered serendipitously. For example, the drug amantadine was first introduced to treat respiratory infections. However, a few years later, a patient with Parkinson’s disease experienced a dramatic improvement of her disease symptoms while taking the drug to treat the flu. This observation sparked additional research. Now, amantadine is approved by the Food Drug Administration as both an antiviral and an antiparkinsonian drug. But, we can not only rely on chance to find a treatment for an orphan disease,” said Dr. Michal Brylinski, the head of the Computational Systems Biology group at LSU.
The Latest on: Drug repositioning
- Drug Repurposing: Biomedical Tools and Research Techniques on December 14, 2018 at 3:23 am
As a result, the number of new potential drugs that actually become drugs is very low. Repurposing (or repositioning) existing drugs makes the drug discovery process much shorter because the initial p... […]
- Immune-checkpoint Drugs in Oncology Analytical Tool, 2018 - ResearchAndMarkets.com on December 13, 2018 at 9:45 am
Immune-checkpoint Drugs in Oncology: Analytical Tool is the must have handbook ... Outcome of Clinical TrialsIndication Selection & Expansion ChoicesDrug Repositioning Opportunities […]
- Drug Repositioning Helps to Identify New Anti-epilepsy Drugs on December 12, 2018 at 12:21 am
Drug repositioning is a process of identifying new applications for existing drugs. It is an attractive concept for fastening the drug testing on humans for medical needs which are not met. In a new s... […]
- Drug repositioning strategy identifies potential new treatments for epilepsy on December 11, 2018 at 3:55 pm
Drug repositioning-- taking known drugs and identifying new applications for them--is an attractive concept for speeding up the process of bringing drugs to human testing for unmet medical needs. In a ... […]
- Artificial intelligence in pharma, health care: at the crossroads of hype and reality on December 6, 2018 at 1:47 am
But along with enthusiasm in areas as diverse as phenotypic screening, drug repositioning, and analysis of CT scans, we are also finding a growing skepticism: What is real and what is hype? An example ... […]
- Cerebain Initiates Repositioning and Review of Business and Corporate Strategic Growth Plan on December 4, 2018 at 4:30 am
Cerebain Biotech Corp. CBBT, +21.00% (the “Company” or “Cerebain”) today announced that it has initiated a repositioning and review of its ... invasive implantable device and a synthetic drug solution ... […]
- Small-Cap Snapshot: QBioMed sparks interest after buying cancer pain drug Metastron from GE Healthcare on November 28, 2018 at 8:45 am
In return for the drug, Q BioMed will pay GE Healthcare an undisclosed ... To help shore up its financial performance, the Florida company unveiled a brand repositioning program, which includes the de... […]
- Drug Repositioning With a GRAKN.AI Knowledge Graph for Bioinformatics on October 30, 2018 at 3:27 am
Start coding something amazing with the IBM library of open source AI code patterns. Content provided by IBM. Drug repositioning (also known as drug repurposing) is the application of existing drugs a... […]
- AMPEL's System For Drug Repositioning Confirmed By Success Of Phase 2 Trial Of Stelara In Lupus on October 25, 2018 at 1:32 pm
CHICAGO, Oct. 25, 2018 /PRNewswire/ -- AMPEL BioSolutions is excited to announce proof-of-principle for a multi-pronged approach to rank small molecules and biologics for safe, effective treatment of ... […]
- Old drug, new hope for pediatric brain cancer on October 25, 2018 at 7:41 am
This process is called systematic drug repositioning, and it uses computational modeling methods to compare an approved drug's gene expression profiles – that is, what genes it works with or against – ... […]
via Google News and Bing News